Lexaria Bioscience Heads to BIO Convention to Boost Drug Delivery Partnerships

Lexaria Bioscience Corp. (NASDAQ: LEXX) is set to attend the BIO International Convention (“BIO”) from June 22-25 in San Diego, CA, marking a strategic move to expand its business development (BD) program. The company, a global innovator in oral drug delivery platforms, credits its attendance at last year’s BIO convention as a catalyst for a greatly expanded BD program now delivering positive results. CEO Richard Christopher stated, “We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference.” The company is leveraging the convention—the largest of its kind with over 20,000 attendees—to build on this momentum, having already reserved meetings and expecting to be fully booked given strong industry interest.

Lexaria’s proprietary DehydraTECH™ drug delivery platform is at the core of its BD efforts. This patented technology improves how drugs enter the bloodstream via oral delivery, enhancing bio-absorption, reducing side-effects, and enabling some drugs to cross the blood-brain barrier more effectively. With 65 granted patents and a licensed in-house research laboratory, Lexaria is targeting collaborations with a wide range of partners, from small biotech firms to global pharmaceutical giants. The company’s BD program has already generated multiple discussions and potential partnerships, though specific details remain confidential. Lexaria intends to thoroughly evaluate each opportunity to pursue those best for shareholders.

The BIO convention is a key venue for intra-industry collaborations, with over 66,000 partnering meetings at the 2025 event. Lexaria’s multi-faceted BD program is designed to inform prospective partners of DehydraTECH’s benefits, and the company continues to develop early-stage leads. As Lexaria ramps up its presence at BIO, it aims to convert these interactions into concrete developments that can be publicly disclosed. The company’s focus on oral drug delivery and its robust IP portfolio position it as a significant player in the pharmaceutical and biotechnology sectors, with the potential to transform drug delivery methods.